RECITALSNonexclusive License Agreement • September 5th, 2002 • Gen Probe Inc • Services-commercial physical & biological research
NONEXCLUSIVE LICENSE AGREEMENTNonexclusive License Agreement • May 5th, 2020 • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and (“*****”), a corporation having a principal place of business at , is effective on the day of , 20 (“Effective Date”).
AMENDMENT #1 TO THE NONEXCLUSIVE LICENSE AGREEMENT FACTOR IX VECTOR PRODUCTION TECHNOLOGYNonexclusive License Agreement • July 17th, 2020 • Freeline Therapeutics Holdings PLC • Biological products, (no disgnostic substances) • New York
BACKGROUNDNonexclusive License Agreement • April 26th, 2006 • Alsius Corp • California
NONEXCLUSIVE LICENSE AGREEMENT UNDER VYSIS’ COLLINS PATENTSNonexclusive License Agreement • November 5th, 2009 • Gen Probe Inc • Surgical & medical instruments & apparatus
THIS NONEXCLUSIVE LICENSE AGREEMENT (the “AGREEMENT”) is made and is effective the 22nd day of June, 1999 by and between Gen-Probe Incorporated (“GEN-PROBE”), a Delaware corporation having its principal place of business in San Diego, CA and Vysis, Inc. (“VYSIS”), a Delaware corporation having its principal place of business in Downers Grove, IL WITNESSETH:
AMENDED AND RESTATED NONEXCLUSIVE LICENSE AGREEMENT FOR COVID-19 RELATED TECHNOLOGYNonexclusive License Agreement • June 9th, 2021 • Ocean Biomedical, Inc. • Pharmaceutical preparations • California
This Amended and Restated Non-Exclusive License Agreement for Covid-19 Related Technology (“Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Ocean Promise, Inc. (“Ocean”), a wholly owned subsidiary of Ocean Biomedical, Inc. (“OBM”) and a corporation having a principal place of business at 19W060 Avenue LaTours OakBrook IL 60523 is effective on the March 3, 2021 (“Effective Date”), and supersedes and replaces that certain Non-Exclusive License Agreement for Covid-19 Related Technology, dated June 25, 2020, by and between Stanford and OBM (“Original Agreement”).
NONEXCLUSIVE LICENSE AGREEMENTNonexclusive License Agreement • July 26th, 2013 • Neurocrine Biosciences Inc • Biological products, (no disgnostic substances) • New York
THIS NONEXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered into this 27th day of August 1999 (the “EFFECTIVE DATE”), by and between Neurocrine Biosciences, Inc., a Delaware corporation having its principal place of business at 10555 Science Center Drive, San Diego, CA 92121 (“Neurocrine”), and the MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK, A New York corporation having its principal place of business at One Gustave L. Levy Place, New York, New York 10029-6574 (“Licensor’’).
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. NONEXCLUSIVE LICENSE AGREEMENTNonexclusive License Agreement • March 3rd, 2011 • Ligand Pharmaceuticals Inc • Pharmaceutical preparations • Kansas
This License Agreement is entered into as of the 4th day of June, 1996 (the “Effective Date”) by and between Pfizer Inc., a Delaware corporation having an office at 235 East 42nd Street, New York, New York 10017 and its Affiliates (“Pfizer”), and the University of Kansas, a state educational institution of the State of Kansas with a place of business at Office of Research Support and Grants Administration, Strong Hall, Lawrence, Kansas 66045 and its Affiliates (“KU”) (each individually a “Party” and collectively the “Parties”).
CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDED AND RESTATED NONEXCLUSIVE LICENSE AGREEMENT FOR COVID-19 RELATED TECHNOLOGYNonexclusive License Agreement • February 4th, 2022 • Ocean Biomedical, Inc. • Pharmaceutical preparations • California
This Amended and Restated Non-Exclusive License Agreement for Covid-19 Related Technology (“Agreement”) between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Ocean Promise, Inc. (“Ocean”), a wholly owned subsidiary of Ocean Biomedical, Inc. (“OBM”) and a corporation having a principal place of business at 19W060 Avenue LaTours OakBrook IL 60523 is effective on the March 3, 2021 (“Effective Date”), and supersedes and replaces that certain Non-Exclusive License Agreement for Covid-19 Related Technology, dated June 25, 2020, by and between Stanford and OBM (“Original Agreement”).
NONEXCLUSIVE LICENSE AGREEMENTNonexclusive License Agreement • May 5th, 2020
This material is licensed by the International Code Council, Inc.® (ICC®) to users for their use only on the terms set out below. Please read the following terms and conditions carefully and if you do not agree, do not install the software. By installing the contents herein on your PDA/ Computer, you agree to be bound by the terms listed below.
NONEXCLUSIVE LICENSE AGREEMENTNonexclusive License Agreement • March 16th, 2020 • California
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and (“*****”), a corporation having a principal place of business at , is effective on the day of , 20 (“Effective Date”).
Nonexclusive License Agreement between AnorMED, Inc. and North American Scientific, Inc.Nonexclusive License Agreement • March 5th, 2002 • North American Scientific Inc • In vitro & in vivo diagnostic substances • British Columbia
This Nonexclusive License Agreement ("Agreement") is entered into by and between AnorMED, Inc., a corporation doing business in British Columbia, Canada ("ANORMED"), and North American Scientific, Inc., organized and existing under the laws of Delaware ("LICENSEE"), on July 20, 2001 ("Effective Date").
NONEXCLUSIVE LICENSE AGREEMENTNonexclusive License Agreement • November 1st, 2006 • Ithaka Acquisition Corp • Blank checks • California
This Agreement is effective May 14, 1999, between Alsius Corporation with offices at #5 Jenner, Suite 150, Irvine, CA 92618-3808 (“ALSIUS”) and Baxter Healthcare Corporation, acting through its CardioVascular Group business unit with offices at 17211 Red Hill Avenue, Irvine, CA. 92614 (“BAXTER”).
NONEXCLUSIVE LICENSE AGREEMENTNonexclusive License Agreement • May 23rd, 2005 • A.C.T. Holdings, Inc. • Pharmaceutical preparations • Massachusetts
This Nonexclusive License Agreement (“Agreement”) is made and entered into this 1st day of May, 2001 (the “EFFECTIVE DATE”), by and between Advanced Cell Technology, Inc., a Delaware corporation with offices located at One Innovation Drive, Worcester, Massachusetts 01605 (“ACT”), and Immerge BioTherapeutics, Inc., a Delaware corporation with offices located at Building 75, Third Avenue, Charlestown, MA 02129 (“LICENSEE”) (ACT and LICENSEE sometimes hereinafter referred to as the “parties”). As set forth below, the University of Massachusetts, a public institution of higher education of the Commonwealth of Massachusetts (the “University”), has agreed to certain provisions of this Agreement.
Amendment No. 1 to Nonexclusive License AgreementNonexclusive License Agreement • March 5th, 2002 • North American Scientific Inc • In vitro & in vivo diagnostic substances
This Amendment No. 1 (this "Amendment") is entered into by and between AnorMED, Inc., a corporation doing business in British Columbia, Canada ("ANORMED"), and North American Scientific, Inc., organized and existing under the laws of Delaware ("LICENSEE") as of February 14, 2002.
